![Tumore rene. Combinazione di Pembrolizumab e Axitinib in prima linea riduce del 47% rischio morte - Quotidiano Sanità Tumore rene. Combinazione di Pembrolizumab e Axitinib in prima linea riduce del 47% rischio morte - Quotidiano Sanità](https://www.quotidianosanita.it/img_prima/front3387805.jpg)
Tumore rene. Combinazione di Pembrolizumab e Axitinib in prima linea riduce del 47% rischio morte - Quotidiano Sanità
![Single nucleotide polymorphisms in angiogenesis-related genes and outcomes from antiangiogenic therapies in renal cell carcinoma: really a step towards personalized oncology, or not at all? - Porta - Annals of Translational Medicine Single nucleotide polymorphisms in angiogenesis-related genes and outcomes from antiangiogenic therapies in renal cell carcinoma: really a step towards personalized oncology, or not at all? - Porta - Annals of Translational Medicine](https://cdn.amegroups.cn/journals/amepc/files/journals/16/articles/23765/public/23765-PB3-4423-R1.png/w300)
Single nucleotide polymorphisms in angiogenesis-related genes and outcomes from antiangiogenic therapies in renal cell carcinoma: really a step towards personalized oncology, or not at all? - Porta - Annals of Translational Medicine
![Nefrologia, Chirurgia urologica e ricerche Nanotech: nasce a Pavia l'Oncologia Traslazionale - insalutenews.it Nefrologia, Chirurgia urologica e ricerche Nanotech: nasce a Pavia l'Oncologia Traslazionale - insalutenews.it](https://www.insalutenews.it/in-salute/wp-content/uploads/2018/09/roberto-pedretti-camillo-porta-e-antonio-bernardo-maugeri.jpeg)
Nefrologia, Chirurgia urologica e ricerche Nanotech: nasce a Pavia l'Oncologia Traslazionale - insalutenews.it
![JPM | Free Full-Text | Validation of a Novel Three-Dimensional (3D Fusion) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study JPM | Free Full-Text | Validation of a Novel Three-Dimensional (3D Fusion) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study](https://www.mdpi.com/jpm/jpm-12-00727/article_deploy/html/images/jpm-12-00727-g001.png)
JPM | Free Full-Text | Validation of a Novel Three-Dimensional (3D Fusion) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study
![PDF) Simian virus 40-like DNA sequences and large-T antigen-retinoblastoma family protein pRb2/p130 interaction in human mesothelioma PDF) Simian virus 40-like DNA sequences and large-T antigen-retinoblastoma family protein pRb2/p130 interaction in human mesothelioma](https://i1.rgstatic.net/publication/13510433_Simian_virus_40-like_DNA_sequences_and_large-T_antigen-retinoblastoma_family_protein_pRb2p130_interaction_in_human_mesothelioma/links/5b0d7fa1a6fdcc809958d955/largepreview.png)
PDF) Simian virus 40-like DNA sequences and large-T antigen-retinoblastoma family protein pRb2/p130 interaction in human mesothelioma
![Efficacy of Nivolumab plus Ipilimumab According to Number of IMDC Risk Factors in CheckMate 214 - European Urology Efficacy of Nivolumab plus Ipilimumab According to Number of IMDC Risk Factors in CheckMate 214 - European Urology](https://www.europeanurology.com/cms/asset/d630f8f0-cc62-467e-b182-5fb48a1a42f7/gr1.jpg)
Efficacy of Nivolumab plus Ipilimumab According to Number of IMDC Risk Factors in CheckMate 214 - European Urology
![Frontiers | Artificial intelligence-based prediction of overall survival in metastatic renal cell carcinoma Frontiers | Artificial intelligence-based prediction of overall survival in metastatic renal cell carcinoma](https://www.frontiersin.org/files/MyHome%20Article%20Library/1021684/1021684_Thumb_400.jpg)
Frontiers | Artificial intelligence-based prediction of overall survival in metastatic renal cell carcinoma
![Camillio PORTA | Università degli Studi di Bari Aldo Moro, Bari | Università di Bari | Dipartimento di Scienze Biomediche ed Oncologia Umana (DIMO) | Research profile Camillio PORTA | Università degli Studi di Bari Aldo Moro, Bari | Università di Bari | Dipartimento di Scienze Biomediche ed Oncologia Umana (DIMO) | Research profile](https://i1.rgstatic.net/ii/profile.image/963173356167168-1606649831047_Q512/Camillio-Porta-2.jpg)
Camillio PORTA | Università degli Studi di Bari Aldo Moro, Bari | Università di Bari | Dipartimento di Scienze Biomediche ed Oncologia Umana (DIMO) | Research profile
![Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale | Future Oncology Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale | Future Oncology](https://www.futuremedicine.com/pb-assets/Infographics/fon-2018-0745-1548696006543.gif)
Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale | Future Oncology
![GU-CA-COVID: a clinical audit among Italian genitourinary oncologists during the first COVID-19 outbreak - Melissa Bersanelli, Sebastiano Buti, Mimma Rizzo, Alessio Cortellini, Carlo Cattrini, Francesco Massari, Cristina Masini, Maria Giuseppa Vitale ... GU-CA-COVID: a clinical audit among Italian genitourinary oncologists during the first COVID-19 outbreak - Melissa Bersanelli, Sebastiano Buti, Mimma Rizzo, Alessio Cortellini, Carlo Cattrini, Francesco Massari, Cristina Masini, Maria Giuseppa Vitale ...](https://journals.sagepub.com/cms/10.1177/17562872211054302/asset/images/large/10.1177_17562872211054302-fig1.jpeg)
GU-CA-COVID: a clinical audit among Italian genitourinary oncologists during the first COVID-19 outbreak - Melissa Bersanelli, Sebastiano Buti, Mimma Rizzo, Alessio Cortellini, Carlo Cattrini, Francesco Massari, Cristina Masini, Maria Giuseppa Vitale ...
![Edgar V. Lerma 🇵🇭 on Twitter: "Renal Cell Carcinoma Staging #Nephpearls https://t.co/3D5YaTBnlJ" / Twitter Edgar V. Lerma 🇵🇭 on Twitter: "Renal Cell Carcinoma Staging #Nephpearls https://t.co/3D5YaTBnlJ" / Twitter](https://pbs.twimg.com/media/EY9eWk_WoAYgfb2.jpg)